Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) ; volume:20 ; number:1 ; day:15 ; month:3 ; year:2018 ; pages:1-11 ; date:12.2018
Arthritis Research & Therapy ; 20, Heft 1 (15.3.2018), 1-11, 12.2018
- Contributor
-
Nash, Peter
Mease, Philip J.
McInnes, Iain B.
Rahman, Proton
Ritchlin, Christopher T.
Blanco, Ricardo
Dokoupilova, Eva
Andersson, Mats
Kajekar, Radhika
Mpofu, Shephard
Pricop, Luminita
SpringerLink (Online service)
- DOI
-
10.1186/s13075-018-1551-x
- URN
-
urn:nbn:de:1111-201805242633
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nash, Peter
- Mease, Philip J.
- McInnes, Iain B.
- Rahman, Proton
- Ritchlin, Christopher T.
- Blanco, Ricardo
- Dokoupilova, Eva
- Andersson, Mats
- Kajekar, Radhika
- Mpofu, Shephard
- Pricop, Luminita
- SpringerLink (Online service)
Other Objects (12)
Secukinumab: A Review in Psoriatic Arthritis
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
Vitiligo with Progressive Repigmentation during Secukinumab Treatment in a Patient with Psoriatic Arthritis: A Case Report
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting
Secukinumab: A Review in Psoriatic Arthritis
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
Vitiligo with Progressive Repigmentation during Secukinumab Treatment in a Patient with Psoriatic Arthritis: A Case Report
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting
Secukinumab: A Review in Psoriatic Arthritis
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
Vitiligo with Progressive Repigmentation during Secukinumab Treatment in a Patient with Psoriatic Arthritis: A Case Report
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies